A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitum...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2011
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049870/
https://ncbi.nlm.nih.gov/pubmed/21135857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.226
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller